๐ Week Recap: FBRX +55% on vitiligo win, BYRN -25% on Q2 miss โ JPMorgan & CPI arrive next week
Markets closed the week mixed โ S&P 500 +0.4%, Nasdaq +0.5%, Dow -0.9%. Forte Biosciences ($FBRX) was the standout winner, surging ~55% after its FB102 drug hit a statistically significant 29.6% improvement vs. placebo in a Phase 1b vitiligo trial. Byrna Technologies ($BYRN) was the week's biggest casualty, crashing ~25% after Q2 revenue collapsed 42% YoY to $16.4M โ badly missing the $22.2M estimate. Huge week ahead: JPMorgan, Goldman Sachs, Citigroup, and BofA all kick off earnings season starting Monday, and June CPI prints Tuesday โ could set the tone for the whole market. Not financial advice. Are you bullish or cautious heading into bank earnings season?
โก 43 buzzing
415 views
๐ 0 subscribed